On Jan. 21, 2025, the FDA approved treosulfan (Grafapex, medac GmbH) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome.